Chris Shibutani
Stock Analyst at Goldman Sachs
(3.59)
# 769
Out of 5,182 analysts
94
Total ratings
56.25%
Success rate
24.94%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $59.72 | +67.45% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $19.15 | -84.33% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $7.32 | +104.92% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $33.73 | -5.13% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $102.06 | +34.23% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $21.00 | +57.14% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $566.99 | -46.74% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $49.65 | +2.72% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $225.34 | -31.22% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $16.88 | -76.30% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $13.16 | +51.98% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $868.27 | -16.73% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $11.74 | +121.47% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $128.04 | +19.49% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $197.38 | -12.35% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $86.74 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $57.78 | +19.42% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $23.36 | -44.35% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $131.67 | -82.53% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $86.68 | -40.01% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.79 | +123.96% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $12.96 | +38.89% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $26.33 | -35.43% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.99 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.51 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $59.72
Upside: +67.45%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $19.15
Upside: -84.33%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $7.32
Upside: +104.92%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $33.73
Upside: -5.13%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $102.06
Upside: +34.23%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $21.00
Upside: +57.14%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $566.99
Upside: -46.74%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $49.65
Upside: +2.72%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $225.34
Upside: -31.22%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $16.88
Upside: -76.30%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $13.16
Upside: +51.98%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $868.27
Upside: -16.73%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $11.74
Upside: +121.47%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $128.04
Upside: +19.49%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $197.38
Upside: -12.35%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $86.74
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $57.78
Upside: +19.42%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $23.36
Upside: -44.35%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $131.67
Upside: -82.53%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $86.68
Upside: -40.01%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.79
Upside: +123.96%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $12.96
Upside: +38.89%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $26.33
Upside: -35.43%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.99
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $7.51
Upside: -